Pharmaceutical Giant Faces Severe Credit Rating Downgrade
On September 5, China’s National Healthcare Security Administration (NHSA) released its 14th list of pharmaceutical companies deemed ‘seriously’ or ‘particularly seriously’ dishonest in pricing and procurement信用评价. The updated list included 63 companies nationwide, with 16 new additions. Among them was Guangdong Yifang Pharmaceutical Co., Ltd.—one of the ‘big six’ manufacturers of traditional Chinese medicine formula granules.
The company’s dishonesty was related to commercial bribery, one of the more severe violations under the pharmaceutical pricing and procurement credit evaluation system. This case highlights the ongoing struggle against corruption in China’s healthcare sector and raises questions about the integrity of industry leaders.
Understanding the Violation and Immediate Response
In September 2023, Yunnan Province’s centralized drug procurement platform completed its credit evaluation of companies involved in commercial bribery cases during the fourth quarter of 2022 and the first quarter of 2023. Guangdong Yifang received a notice regarding its impending失信 rating.
The company quickly issued an apology, stating: ‘We verified the situation immediately and implemented a series of corrective measures. We are strengthening our corporate integrity culture and improving compliance management mechanisms to strictly prevent such issues from recurring.’ Yifang pledged to address operational problems rigorously, maintain discipline, and continuously enhance measures to combat corruption.
Possible Connection to Hospital President’s Downfall
Industry observers speculate that Yifang’s失信 rating may be linked to the downfall of Huang Zhongyi (黄钟义), former president of Jianchuan County Traditional Chinese Medicine Hospital in Yunnan. According to a March 2023 criminal verdict from Jianchuan County People’s Court, Huang used his position to facilitate medical drug, equipment, and device purchases for personal gain, accepting bribes totaling 98,000 yuan.
Court documents revealed that before the Spring Festival in 2014 and the Mid-Autumn Festival in 2015, Huang accepted two bribe payments totaling 8,000 yuan in cash from Wang Mou1 (王某1), a sales representative of Guangdong Yifang, which had drug procurement dealings with the hospital. Additionally, during the 2018 Mid-Autumn Festival, Wang gifted Huang an OPPO phone and a box of mooncakes.
Broader Implications of the Scandal
While the above bribe was relatively small, analysts note that under the credit rating rules, a single bribe must exceed 300,000 yuan to warrant a ‘serious dishonesty’ designation. The fact that Yifang was rated ‘seriously dishonest’ by Guangdong Province—not Yunnan—suggests additional, possibly larger, violations.
In August 2023, a leaked audit report from the National Audit Office indicated that from 2021 to May 2023, three pharmaceutical manufacturers in Guangdong paid 40.77 billion yuan to 1,936 third-party promotion companies, falsely labeling these payments as ‘service fees.’ Guangdong Yifang was involved in 23.9 billion yuan of these funds.
Industry-Wide Challenges and Regulatory Crackdowns
Traditional Chinese medicine formula granules were long monopolized by six major producers, including Yifang, Shenzhen Sanjiu, and Beijing Kangrentang. In early 2021, China ended a 20-plus-year production pilot program, fully opening up the market. The Shandong联盟 has since organized a national centralized procurement program for these granules, diminishing the dominance of established players.
Amid this transition, various irregularities have emerged. A recent case that attracted significant attention involved a judicial document published in August by Jiangxi Gao’an Court. A representative from a traditional medicine granule company offered kickbacks totaling 1.926 million yuan to 33 doctors at two hospitals in Gao’an, with rebate rates ranging from 8% to 15%.
High Sales Costs and IPO Failures
The company implicated was Baishin Pharmaceutical, which failed its 2023 IPO on the ChiNext board. It faced scrutiny over its high sales expenses, with ‘academic promotion fees’ accounting for more than 50% of its sales revenue. The traditionally high pricing of formula granules allowed ample ‘gray space’ for commercial bribery, an open secret in the industry.
China’s Healthcare Sector Moving Toward Transparency
China’s pharmaceutical market is rapidly moving away from the era of ‘high pricing, high kickbacks.’ NHSA data shows that of the 440 billion yuan saved through centralized procurement, over 360 billion has been redirected to innovative drug development. This shift in funding is expected to bring patients more life-saving and reliable medications.
The case of Guangdong Yifang serves as a stark reminder that regulatory bodies are intensifying efforts to cleanse the industry. Companies must abandon outdated, aggressive marketing tactics or face severe penalties. The push for integrity is not just about punishment but about fostering a sustainable, ethical healthcare ecosystem.
Key Takeaways and Future Outlook
– Commercial bribery remains a significant issue in China’s pharmaceutical industry, with major players like Guangdong Yifang facing serious信用 consequences.
– The National Healthcare Security Administration’s信用评价 system is becoming increasingly stringent, targeting both individual bribes and systemic malpractices.
– The traditional Chinese medicine formula granule sector, once dominated by six giants, is undergoing rapid change with market liberalization and centralized procurement.
– Companies must enhance compliance mechanisms and corporate integrity to avoid penalties and reputational damage.
– China’s healthcare reforms are redirecting funds from cost savings toward innovation, benefiting patients with better access to advanced treatments.
As the industry evolves, stakeholders must prioritize ethical practices and transparency. The NHSA’s ongoing crackdown on commercial bribery signals a new era of accountability. For pharmaceutical companies, the choice is clear: adapt to the new norms or risk being left behind.
Stay informed about regulatory changes and industry best practices by following updates from the National Healthcare Security Administration and other authoritative sources. Together, we can build a healthier, more honest healthcare system for all.